Protective renal effect of dapagliflozin in type 2 diabetes

被引：0
|
作者：
Dobler, Gabriele
机构：
来源：
DIABETOLOGIE UND STOFFWECHSEL | 2023年 / 18卷 / 01期
关键词：
D O I：
10.1055/a-1933-5902
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In vorhergehenden Studien wurde bereits nachgewiesen, dass Natrium-Glucose-Cotransporter-2-Inhibitoren (SGLT2-Inhibitoren) das Progressionsrisiko einer moderaten bis schweren albuminurischen Nierenerkrankung mindern. Mosenzon et al. untersuchten in einer Post-hoc-Analyse die Auswirkungen von Dapagliflozin auf die Verschlechterung der Nierenfunktion bei Typ-2-Diabetes. Der Fokus lag auf der Subpopulation von Patient/innen mit niedrigem renalem Risiko.
引用
收藏
页码：17 / 18
页数：2
相关论文
共 50 条
  • [41] Dapagliflozin (Farxiga) for Type 2 Diabetes Mellitus
    Pong, Clinton K.
    Maxted, George E.
    [J]. AMERICAN FAMILY PHYSICIAN, 2015, 91 (12) : 828 - +
  • [42] Dapagliflozin/Saxagliptin (Qtern) for Type 2 Diabetes
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2018, 60 (1543): : 55 - 56
  • [43] Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus
    Aylsworth, Andrew
    Dean, Zachary
    VanNorman, Cody
    Okere, Arinze Nkemdirim
    [J]. ANNALS OF PHARMACOTHERAPY, 2014, 48 (09) : 1202 - 1208
  • [44] Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes
    Liu, Jia
    Chang, Xiaona
    Ding, Xiaoyu
    He, Xueqing
    Wang, Jiaxuan
    Wang, Guang
    [J]. DIABETOLOGY & METABOLIC SYNDROME, 2023, 15 (01):
  • [45] Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes
    Jia Liu
    Xiaona Chang
    Xiaoyu Ding
    Xueqing He
    Jiaxuan Wang
    Guang Wang
    [J]. Diabetology & Metabolic Syndrome, 15
  • [46] Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment
    Fioretto, Paola
    Stefansson, Bergur V.
    Johnsson, Eva
    Cain, Valerie A.
    Sjostrom, C. David
    [J]. DIABETOLOGIA, 2016, 59 (09) : 2036 - 2039
  • [47] Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment
    Paola Fioretto
    Bergur V. Stefansson
    Eva Johnsson
    Valerie A. Cain
    C. David Sjöström
    [J]. Diabetologia, 2016, 59 : 2036 - 2039
  • [48] Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
    DeFronzo, Ralph A.
    Hompesch, Marcus
    Kasichayanula, Sreeneeranj
    Liu, Xiaoni
    Hong, Ying
    Pfister, Marc
    Morrow, Linda A.
    Leslie, Bruce R.
    Boulton, David W.
    Ching, Agatha
    LaCreta, Frank P.
    Griffen, Steven C.
    [J]. DIABETES CARE, 2013, 36 (10) : 3169 - 3176
  • [49] Comparison of Renal and Metabolic Effects of Empagliflozin and Dapagliflozin on Type 2 Diabetes-Induced Rats
    Herdan, Nadir Emre
    Gursu, Meltem
    Selek, Sahabettin
    Coban, Ganime
    Kazancioglu, Rumeyza
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 663 - 663
  • [50] Dapagliflozin and Insulin Resistance in Patients with Type 2 Diabetes
    Katz, Arie
    Yeh, Helen
    [J]. DIABETES, 2015, 64 : A304 - A305
12345